New Delhi, India and Tel Aviv, Israel: Pathology industry leader Dr. LalPathLabs has
collaborated with Artificial intelligence (AI) powered cancer diagnostics provider Ibex Medical
Analytics to deploy an AI platform that supports pathologists during routine cancer diagnosis
to improve the quality and turnaround time of cancer tests.
As the detection and diagnosis by pathologists is an essential step for oncologists to provide
the right treatment, with a rise in cancer prevalence and advances in personalized medicine
have resulted in growing diagnostic complexity, significantly increasing the workload of
pathologists. They prefer AI-enhanced workflow as it improves the quality and efficiency of
cancer diagnosis by providing assistance to pathologists, resulting in better patient care.
Talking about the increasing use of Artificial Intelligence to provide medical services, Stuart
Shand, Chief Commercial Officer at Ibex Medical Analytics said “Ibex is committed to
providing every patient with a precise, timely and personalized cancer diagnosis, made
available by our AI technology that supports real-world needs from physicians. Working
together with Philips and Dr. LalPathLabs will empower their pathologists to provide highly
accurate and prompt diagnoses with a potential of directly impacting prognosis for patients is
becoming the new standard in cancer care, a vision embraced by our companies.”
Galen platform by Ibex was recently given breakthrough devicedesignation by the U.S. Food
and Drug Administration (FDA) for improving the quality of cancer diagnosis, implementing
real-time quality control, reducing diagnosis time and boosting productivity.
Further, it is CE marked in Europe for breast and prostate cancer detection in multiple
workflows. With the addition of Ibex’s Galen platform, pathologists at DrLalPathlabs can
utilize clinical-grade AI insights on multiple types of tissues, supporting quality diagnosis
delivered on shorter turnaround times.
Ibex’s AI technology and Philips’ IntelliSite pathology solution showed impressive results
across multiple clinical studies and in live clinical deployments in Europe and the United
States and were approved for medical use.
Speaking about the improvement in diagnosis that AI will bring, Dr Reena Nakra, Principal
Director Lab management and Technical Excellence, Dr Lal PathLabs Ltd said “This cuttingedge AI technology will help our pathologists quickly prioritise urgent cases and improve
quality by adding an ‘AI review’.These AI-generated insights include cancer heatmaps,
tumour grading and measurement and streamlined reporting tools enabling a digital
assistance to the oncopathologist.”
